Metadata record for the article: Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer
Creators: name: Liu, Ying L.
name: Bager, Cecilie Liv
name: Willumsen, Nicholas
name: Ramchandani, Divya
name: Kornhauser, Naomi
name: Ling, Lu
name: Cobham, Marta
name: Andreopoulou, Eleni
name: Cigler, Tessa
name: Moore, Anne
name: LaPolla, Dayle
name: Fitzpatrick, Veronica
name: Ward, Maureen
name: Warren, J David
name: Fischbach, Claudia
name: Mittal, Vivek
name: Vahdat, Linda T.
Publisher: name: figshare
Year: 2021
Subjects: subject: 69999 Biological Sciences not elsewhere classified
subject: FOS: Biological sciences
subject: 119999 Medical and Health Sciences not elsewhere classified
subject: FOS: Other medical sciences
subject: Cancer
subject: Biomarkers

description: <b>Summary</b><br> This metadata record provides details of the data supporting the claims of the related article: “Tetrathiomolybdate (TM)-associated copper depletion influences collagen remodeling and immune response in the pre-metastatic niche of breast cancer”. The related study sought to elucidate the mechanism of tetrathiomolybdate (TM) by exploring its effects on collagen processing and immune function in the tumour microenvironment (TME). Type of data: flow cytometry; clinical data Subject of data: <i>Homo sapiens; </i>Mouse syngeneic TNBC cell lines EO771 (obtained from Robin Anderson lab, La Trobe University, Australia) and its lung metastatic derivative EO771.ML1 (derived according to standard protocol at Mittal lab, WCM) Sample size: 75 Population characteristics: &gt;=18 years of age; histologically confirmed stage II TNBC, stage III, or stage IV with no evidence of disease of all molecular subtypes; no radiographic, biochemical, or physical evidence of active breast cancer; more than 6 weeks from previous therapy including surgery, radiation, chemotherapy, biologic treatment; Eastern Cooperative Oncology Group performance status 0–1 and adequate organ function. Trial registration number: NCT00195091 <b>Data access</b> The data underlying the claims of the related article are contained in the following files: - STATA file ‘TM_Survival_Stage_12-1-2020.dta’ - STATA file ‘TM_Collagen_CPdata_Wide_1-6-2021.dta’ - GraphPad file ‘LungBLI-Flow-IF 08-21-2020.pzfx’ - GraphPad file ‘LungSampleAnalysis 09-24-2018.pzfx’ (also available in .xlsx format) - Excel file ‘TM Demographics all 75 pts.xlsx’ - Excel file ‘AEs all pts 6-2018.xlsx’ - GraphPad file ‘LungFlow 04-28-2020.pzfx’ Authors have chosen not to share the data publicly as they contain ongoing, unpublished work included in other projects. However, the data are available upon request from the corresponding author. <b>Corresponding author(s) for this study</b> Linda T. Vahdat MD MBA. Chief, Cancer Services Memorial Sloan Kettering Physicians at Norwalk Hospital; Member, Breast Medicine Service; 300 East 66th Street, 8th Floor, NY, NY 10065. T 646.888.4282. F 646.888.4913. vahdatl@mskcc.org. <br> <b>Study approval </b> The study was conducted under Weill Cornell Medicine protocol #0309006307 and #0611008853, and under Memorial Sloan Kettering Cancer Center protocol #18-023, and appropriate informed consent was obtained from patients. All animal work was conducted in accordance with a protocol approved by the Institutional Animal Care and Use Committee at Weill Cornell Medicine.